Abstract
The role of non-vitamin K antagonist oral anticoagulants (NOACs) in stroke prevention remains unclear in Asian patients with atrial fibrillation (AF). Therefore, we performed a meta-analysis to compare the efficacy and safety outcomes of NOACs in Asian patients with AF from the real-world settings. The PubMed and Embase databases were systematically searched to identify eligible observational studies until June 2019. The odds ratios (OR) and 95% confidence intervals (CIs) were calculated and then pooled by a random-effects model. A total of 18 observational studies were included. Compared with warfarin, dabigatran (OR, 0.56, 95% CI 0.43–0.73), rivaroxaban (OR, 0.54, 95% CI 0.44–0.67), apixaban (OR, 0.41, 95% CI 0.35–0.48), and edoxaban (OR, 0.19, 95% CI 0.14– 0.25) reduced the risk of major bleeding, while dabigatran (OR, 0.78, 95% CI 0.71–0.85), rivaroxaban (OR, 0.74, 95% CI 0.68–0.82), and edoxaban (OR, 0.29, 95% CI 0.22–0.39) were associated with reduced risks of stroke or systemic embolism. In addition, dabigatran versus apixaban was associated with increased risks of ischemic stroke and gastrointestinal bleeding, while rivaroxaban versus apixaban was associated with elevated risks of stroke or systemic embolism, ischemic stroke, intracranial hemorrhage, and gastrointestinal bleeding. In Asian patients with AF, NOACs are non-inferior to warfarin for stroke prevention, and apixaban may be a better choice compared with dabigatran or rivaroxaban.
Similar content being viewed by others
References
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW (2019) AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation 2019:R665
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 369(22):2093–2104
Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 365(11):981–992
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 365(10):883–891
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 361(12):1139–1151
Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip G (2018) Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 49(1):98–106
Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH (2017) Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation. Stroke. 48(9):2494–2503
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 383(9921):955–962
Li G, Lip GYH, Holbrook A, Chang Y, Larsen TB, Sun X, Tang J, Mbuagbaw L, Witt DM, Crowther M, Thabane L, Levine MAH (2019) Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 34(2):173–190
Wang K, Giugliano RP, Goto S, Chiu C, Lin C, Lai E, Chiang C (2016) Standard dose versus low dose non–vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: a meta-analysis of contemporary randomized controlled trials. Heart Rhythm. 13(12):2340–2347
Wang KL, Lip GY, Lin SJ, Chiang CE (2015) Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke. 46(9):2555–2561
Higgins J, Green S Cochrane handbook for systematic reviews of interventions version 5.1.0[updated March 2011]. Available at: www.cochrane-handbook.org. Accessed June 23, 2019.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 6(7):e1000097
Wells GA, Shea B, O Connell D, Peterson J, Welch V, Losos M, Tugwell P 2014 The Newcastle Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed June 20, 2019.
Zhu W, Wan R, Liu F, Hu J, Huang L, Li J, Hong K (2016) Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review. J Am Heart Assoc. 5(9):e4006
Xiong Q, Chen S, Senoo K, Proietti M, Hong K, Lip GYH (2015) The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: a systemic review and meta-analysis. Int J Cardiol. 195:237–242
Koretsune Y, Yamashita T, Yasaka M, Ono Y, Hirakawa T, Ishida K, Kuroki D, Sumida T, Urushihara H (2019) Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: a claims database analysis. J Cardiol. 73(3):204–209
Jeong HK, Lee KH, Park HW, Yoon NS, Kim MC, Lee N, Kim JS, Ahn Y, Jeong MH, Park JC, Cho JG (2019) Real world comparison of rivaroxaban and warfarin in Korean patients with atrial fibrillation: propensity matching cohort analysis. Chonnam Med J 55(1):54
Chan Y, Lee H, See L, Tu H, Chao T, Yeh Y, Wu L, Kuo C, Chang S, Lip GYH (2019. Epub ahead of print]) Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation. Chest. https://doi.org/10.1016/j.chest.2019.04.108
Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itou S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A (2018) Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation ― findings from the SAKURA AF Registry ―. Circ J. 82(10):2500–2509
Chan YH, See LC, Tu HT, Yeh YH, Chang SH, Wu LS, Lee HF, Wang CL, Kuo CF, Kuo CT (2018) Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc 7(8)
Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH (2018) Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol. 72(8):838–853
Kohsaka S, Katada J, Saito K, Terayama Y (2018) Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data. Curr Med Res Opin. 34(9):1627–1634
Li WH, Huang D, Chiang CE, Lau CP, Tse HF, Chan EW, Wong ICK, Lip GYH, Chan PH, Siu CW (2017) Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project. Clin Cardiol. 40(4):222–229
Cha M, Choi E, Han K, Lee S, Lim W, Oh S, Lip GYH (2017) Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation. Stroke. 48(11):3040–3048
Kohsaka S, Murata T, Izumi N, Katada J, Wang F, Terayama Y (2017) Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Curr Med Res Opin. 33(11):1955–1963
Chan LX, Wong YM, Chia P, Kek ZL (2017) A single institution’s experience with using dabigatran, rivaroxaban and warfarin for prevention of thromboembolism in atrial fibrillation. Proceedings of Singapore Healthcare.;27(1):20-25.
Lee KH, Park HW, Lee N, Hyun DY, Won J, Oh SS, Park HJ, Kim Y, Cho JY, Kim MC, Sim DS, Yoon HJ, Yoon NS, Kim KH, Hong YJ, Kim JH, Ahn Y, Jeong MH, Park JC, Cho JG (2017) Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. Ep Europace 19(suppl_4):v1–v9
Lau WC, Li X, Wong IC, Chan EW (2017) Bleeding-related hos- 478 pital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin. Journal of Thrombosis and Haemostasis, 15(10), 1923-1933
Yap LB, Eng DTS, Sivalingam L, Rusani BI, Umadevan D, Muhammad Z, Koh KW, Aisha B, Hashim MI, Rebo R, Hussin A, Kaur S, Shanmugam R, Omar R (2016) A comparison of dabigatran with warfarin for stroke prevention in atrial fibrillation in an Asian population. Clin Appl Thromb Hemost 22(8):792–797
Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H (2016) Beneficial effect of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation – results of the J-RHYTHM Registry 2. Circ J. 80(4):843–851
Ellis MH, Neuman T, Bitterman H, Dotan SG, Hammerman A, Battat E, Eikelboom JW, Ginsberg JS, Hirsh J (2016) Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study. Eur J Intern Med. 33:55–59
Shiga T, Naganuma M, Nagao T, Maruyama K, Suzuki A, Murasaki K, Hagiwara N (2015) Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: a single-center observational study. J Arrhythm. 31(6):339–344
Ho JCS, Chang AM, Yan BP, Yu CM, Lam YY, Lee VWY (2012) Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Clin Cardiol. 35(12):E40–E45
Chiang C, Okumura K, Zhang S, Chao T, Siu C, Wei Lim T, Saxena A, Takahashi Y, Siong TW (2017) 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 33(4):345–367
Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, Bahit MC, Gersh BJ, Hanna M, Horowitz J, Lopes RD, Wallentin L, Xavier D, Alexander JH (2014) Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J. 168(3):303–309
Lip GY, Larsen TB, Skjoth F, Rasmussen LH (2012) Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 60(8):738–746
Author information
Authors and Affiliations
Contributions
ZB-X, Y-Z, and WG-Z performed the literature search, study selection and data extraction, quality assessment, and statistical analysis. CY-W, J-L, and X-L help check the data to ensure accuracy. ZB-X and Y-Z wrote the original draft, while WG-Z revised the draft. WG-Z edited the manuscript prior to submission to ensure the standard English grammar.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Not required.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Zhengbiao Xue and Yue Zhou are co-first authors
Electronic supplementary material
ESM 1
(PDF 1234 kb)
Rights and permissions
About this article
Cite this article
Xue, Z., Zhou, Y., Wu, C. et al. Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data. Heart Fail Rev 25, 957–964 (2020). https://doi.org/10.1007/s10741-019-09878-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-019-09878-y